XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Net income $ 26,245 $ 21,622
Adjustments to reconcile net income to net cash provided byoperating activities:    
Depreciation and amortization 6,031 5,607
Loss on disposal of property, plant & equipment 7 107
Share-based compensation 3,249 2,253
Deferred income taxes 304 (466)
Change in fair value of contingent consideration 476 3,051
Changes in operating assets and liabilities:    
Receivables, net 4,230 (8,807)
Inventories (7,349) (9,448)
Prepaid expenses and other current assets (1,010) (1,395)
Other assets 951 1,202
Accounts payable 700 4,862
Accrued expenses (2,053) (6,197)
Deferred revenue (2,064) (415)
Income taxes payable (398) (1,470)
Non-qualified deferred compensation plan and other liabilities (6,951) 94
Net cash provided by operating activities 22,368 10,600
Cash flows from investing activities:    
Acquisition of Marble Medical, net of cash acquired (4,612) 0
Additions to property, plant, and equipment (4,503) (4,951)
Proceeds from sale of fixed assets 2 4
Net cash used in investing activities (9,113) (4,947)
Cash flows from financing activities:    
Proceeds from advances on revolving line of credit 45,200 9,000
Payments on revolving line of credit (10,000) (5,000)
Principal payments of long-term debt (32,000) (2,000)
Payment of contingent consideration (188) (5,000)
Principal payments on finance lease obligations (41) (32)
Proceeds from the exercise of stock options 107 680
Payment of statutory withholdings for restricted stock units vested (4,751) (2,413)
Net cash used in financing activities (1,673) (4,765)
Effect of foreign currency exchange rates on cash and cash equivalents (117) (48)
Net increase in cash and cash equivalents 11,465 840
Cash and cash equivalents at beginning of period 5,263 4,451
Cash and cash equivalents at end of period $ 16,728 $ 5,291